NTLA Intellia Therapeutics Inc.

Intellia Therapeutics to Present at October Healthcare Investor Conferences

Intellia Therapeutics to Present at October Healthcare Investor Conferences

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be presenting at the following upcoming investor conferences in October:

Chardan’s 6th Annual Genetic Medicines Conference, New York

Date: Monday, October 3, 2022

Time: 8:30 a.m. ET

Format: Fireside chat

2022 Truist Securities Genetic Medicine Summit, New York

Genome Editing Panel

Date: Thursday, October 20, 2022

Time: 9:00 a.m. ET

Format: Panel discussion

A live webcast of Intellia’s fireside chat at the Chardan conference will be accessible through the Events and Presentations page of the Investors & Media section of the company’s website at . Replay of the webcast will be available on Intellia’s website for at least 30 days following the presentation.

About Intellia Therapeutics

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at . Follow us on Twitter .

Intellia Contacts:

Investors:

Ian Karp

Senior Vice President, Investor Relations and Corporate Communications



Lina Li

Senior Director, Investor Relations and Corporate Communications





EN
26/09/2022

Underlying

NTLAIntellia Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intellia Therapeutics Inc.

 PRESS RELEASE
Free
NTLA Intellia Therap...

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing R...

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 65,200 shares of Intellia’s common s...

October 3, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.59
ERICn Telefonaktiebol...
CE Celanese Corpor... ... (+28)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ERICn TELEFONAKTIEBOLAGET LM ERICSSON
CE CELANESE CORPORATION
ACHC ACADIA HEALTHCARE COMPANY INC.
BJRI BJ'S RESTAURANTS INC.
PTK POET TECHNOLOGIES
NTLA INTELLIA THERAPEUTICS INC.
CRSP CRISPR THERAPEUTICS AG
BH BIGLARI HOLDINGS B
STOK STOKE THERAPEUTICS
TWST TWIST BIOSCIENCE
BEAM BEAM THERAPEUTICS
PCVX VAXCYTE
LUMN LUMEN TECHNOLOGIES INC.
ENVX ENOVIX CORP
ASTS AST SPACEMOBILE INC
ZGN ERMENEGILDO ZEGNA NV
PRME PRIME MEDICINE INC
ENGN ENGENE HOLDINGS INC
RR RICHTECH ROBOTICS INC
NGNE NEUROGENE INC
CRML CRITICAL METALS CORP.
BKKT BAKKT HOLDINGS INC.
MNPR MONOPAR THERAPEUTICS INC.
KLRS KALARIS THERAPEUTICS INC
STEM STEM INC.
RKLB ROCKET LAB CORPORATION
BALY BALLY'S CORPORATION
ANGX ANGEL STUDIOS INC CL A
10/03/25 October 3, 2025 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
NTLA INTELLIA THERAPEUTICS INC.
09/25/25 September 25, 2025 1 EN
 PRESS RELEASE
Free
NTLA Intellia Therap...

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for ...

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinical measures observed at 24 monthsContinue to observe generally favorable safety data with no new drug-related events within the follow-up periodData presented today at the 5th International ATTR Amyloidosis Annual Meet...

September 25, 2025 1 EN
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
MNKD MANNKIND CORP.
BIIB BIOGEN INC.
NTLA INTELLIA THERAPEUTICS INC.
SRRK SCHOLAR ROCK HOLDING CORPORATION
MLTX MOONLAKE IMMUNOTHERAPEUTICS
09/19/25 September 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch